Around 2·5 million deaths and more than 110 million COVID-19 cases have been reported
globally. Although it initially appeared that HIV infection was not a risk factor for COVID-19 or …

Background Factors affecting outcomes of SARS-CoV-2 infection in people living with HIV
are unclear. We assessed the factors associated with SARS-CoV-2 diagnosis and severe …

Background: It is unclear how characteristics, risk factors, and incidence of coronavirus
disease 2019 (COVID-19) in people living with HIV (PLWH) differ from the general population. …

Background: Integrase inhibitors have shown better tolerability than other drugs in clinical
trials, but some post-marketing data have suggested potential differences among them. Aims: …

Background Calcium is an essential ion for pathogen survival and virulence and is involved
in the regulation of the inflammatory response. Hypocalcemia is a common laboratory …

Background The use of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is
mainly based on robust, pivotal clinical trials. Objectives To provide data on clinical use of BIC/…

Purpose Assess the impact of viral load estimated by cycle threshold (Ct) of reverse transcription
real time-polymerase chain reaction (rRT-PCR) and the days from symptoms onset on …

Background In some patients the immune response triggered by SARS-CoV-2 is unbalanced,
presenting an acute respiratory distress syndrome which in many cases requires intensive …

Background Switching from boosted PIs to dolutegravir in people living with HIV (PLWH) with
high cardiovascular risk improved plasma lipids at 48 weeks in the NEAT022 trial. Whether …

Objectives We reviewed the 24 week outcomes of HIV-infected patients from our hospital
who had their ART switched to dolutegravir monotherapy on an individual clinical basis. …